Curative Biosciences, Inc., an orthobiologic start up company based in Woburn, Massachusetts, reports that the company has entered into a research agreement with the Musculoskeletal Transplant Foundation (MTF) in which MTF will evaluate the potential of Curative’s small molecule (DMA).
As stated by Curative Biosciences President & CEO, Mr. Patrick O’Donnell, “ The research agreement with the nation’s leading tissue bank, MTF, is a first, exciting step for the company as we build an organization focused on developing safe, cost-efficient, and clinically effective alternatives to Medtronic’s Infuse™ BMP-2 in the global bone graft substitute market. While Infuse is an exceptional technology, it is clearly not necessary for the majority of spine procedures and the spine surgeon market clearly desires an option that is not necessarily as robust as BMP-2 but demonstrates clinical safety and efficacy at a reasonable price. That is where we are focusing our small molecule and bone-forming peptide technologies”.
According to Mr. Bruce Stroever, President and CEO of MTF, “We are always looking for new ways to improve allografts, and the DMA technology appears very promising. We are hopeful that the studies now underway will confirm that promise.”
Curative Biosciences recently presented at the Cannacord Adams Musculoskeletal Conference in Las Vegas prior to the A.A.O.S Conference. Curative Biosciences is currently seeking strategic partners to collaborate on the development of the Company’s bone-forming peptide technology.